efavirenz and tenofovir
Jul 26, 2013
I was just reading that a study was performed that showed that smaller doses of efavirenz (1/3 less) are just as effective as the current prescribed dose and that there is a new formulation of tenofovir that results in a 90% less plasma concentration than the current formulation. As both of these are found in atripla do you think that the new formulations will be combined into a new atripla. This sounds like a real breakthrough in that atripla is still so widely used and reduced amounts could eliminate some of the side effects that some people suffer.
Response from Dr. Young
Hello and thanks for posting.
You're correct, a study presented at the IAS2013 conference suggests that 400 mg efavirenz is about the same as 600 mg (the standard dose) for people starting therapy. It will likely be a while before this is confirmed and adopted, especially into expensive-to-develop fixed dose formulations.
The new tenofovir formulation, called TAF is under active development, and appears to have lower toxicity ( kidney and bone) than the current TDF formulation. TAF is being developed for fixed dose formulations by Gilead Sciences.
Hope that helps, BY
Get Email Notifications When This Forum Updates or Subscribe With RSS
- What Type Of Specialist To See Regarding Shingles?
- What Is The Difference Between Genital Herpes And Shingles?
- What Do Herpes Looks Like On Your Lips?
- What Happens If You Have Gonorrhea For A Year Without Treatment?
- What Does Herpes Around The Anus Look Like?
- What Does Being Exposed To Herpes Mean?
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.